Pasithea Therapeutics Corp. KTTA

Pasithea Therapeutics reports positive interim Phase 1 data for advanced cancer study showing long-term safety, tolerability and durable clinical activity in MEK/BRAF-pretreated patients, with protocol expansion. Positive Phase 1 results with durable activity in pretreated patients signal major progress toward later trials and potential valuation gains.

Pasithea Therapeutics Corp. (KTTA) obtained FDA Orphan Drug Designation for PAS-004 to treat Amyotrophic Lateral Sclerosis (ALS). Orphan Drug Designation provides Pasithea with regulatory incentives and market exclusivity potential for PAS-004 in ALS treatment.

Pasithea Therapeutics Corp. presented updated interim data from its Phase 1 study of PAS-004, a macrocyclic MEK inhibitor, at the ASCO Annual Meeting 2025. The study showed preliminary clinical activity in patients with heavily pre-treated, refractory solid tumors, with one patient achieving over 5 months of stable disease and tumor volume reduction. The drug demonstrated a favorable pharmacokinetic profile, with no serious adverse events reported. Of the 21 enrolled patients, 10 experienced stable disease, with progression-free survival up to 159 days. The CEO emphasized PAS-004's potential as a best-in-class MEK inhibitor for MAPK pathway-driven tumors. The promising interim results and potential for PAS-004 to serve a significant unmet need in cancer treatment suggest a significant impact on future performance.

Pasithea Therapeutics Corp. (KTTA) appointed Kartik Krishnan, M.D., Ph.D., as Chief Medical Officer to lead clinical development efforts. Appointing an experienced CMO bolsters clinical leadership critical for advancing biotech pipelines and investor confidence.

Pasithea Therapeutics Corp. (KTTA) announces FDA grant of Rare Pediatric Disease Designation (RPDD) to PAS-004 for Neurofibromatosis Type 1 (NF1) treatment. RPDD provides priority review, seven-year exclusivity, and potential priority review voucher, significantly enhancing PAS-004's development prospects and KTTA's pipeline value.

Pasithea Therapeutics Corp. (KTTA) announces FDA grant of Fast Track Designation to PAS-004 for treatment of Neurofibromatosis Type 1 (NF1) associated plexiform neurofibromas (PN) causing significant morbidity. FDA Fast Track Designation accelerates PAS-004 development for NF1-associated PN, significantly boosting KTTA's clinical progress and investor appeal.

Pasithea Therapeutics Corp. provided an update on its PAS-004 clinical programs, outlining timelines for data releases. The company is focused on advancing its research in mental health treatments, particularly for depression and anxiety disorders. Key milestones include upcoming data readouts that are expected to inform future development strategies and potential market positioning. Upcoming data releases and clinical program advancements are likely to significantly impact the company's future performance and market perception.

Pasithea Therapeutics Corp. (KTTA) saw a 10% increase in its stock price, prompting insiders to consider their investments more seriously. The rise in stock value indicates growing investor confidence and potential positive developments within the company. The stock price increase suggests a moderately noticeable influence on market sentiment and potential future performance.

Lawrence Steinman significantly increased his stake in Pasithea Therapeutics Corp. (KTTA) by purchasing 201% more shares. This move indicates a strong belief in the company's potential and may influence investor sentiment positively. Increased insider ownership can enhance market confidence and potentially impact stock performance.

Pasithea Therapeutics Corp. has successfully closed a public offering of common stock, raising $60 million. The funds are intended to support the company's ongoing development of innovative therapies for mental health disorders. This financing is expected to enhance Pasithea's operational capabilities and accelerate its research initiatives. The $60 million raised is a significant boost that can enhance research and development efforts, potentially impacting the company's future trajectory.

Pasithea Therapeutics Corp. (KTTA) has been highlighted as one of the most active stocks in the market, indicating increased trading volume and investor interest. The company's recent developments and market movements have drawn attention, reflecting potential shifts in investor sentiment and market dynamics. Increased trading activity suggests a moderate influence on market sentiment and potential financial performance.

Pasithea Therapeutics Corp. (KTTA) has announced the pricing of a public offering of common stock, aiming to raise $60 million. The offering consists of 6 million shares priced at $10 per share. The company plans to use the proceeds for general corporate purposes, including advancing its clinical programs and expanding its operations. The offering is expected to close on or about October 30, 2023, subject to customary closing conditions. The capital raised may support clinical programs and operational expansion, influencing financial performance moderately.

Pasithea Therapeutics Corp. (KTTA) has been identified as one of the most active stocks in the market, reflecting heightened trading activity and investor interest. The company's recent developments and market movements have contributed to its visibility among investors, indicating potential shifts in market sentiment and engagement with its stock. Increased trading activity suggests a moderate influence on market sentiment and potential interest in the company's future performance.

Pasithea Therapeutics Corp. has received a $1 million award from the ALS Association to conduct a study on the efficacy, safety, and tolerability of its drug PAS-004 for treating Amyotrophic Lateral Sclerosis (ALS). This funding aims to support research that could potentially lead to new treatment options for ALS patients. The funding from the ALS Association could significantly enhance research capabilities and product development for PAS-004, impacting the company's future trajectory.

Pasithea Therapeutics Corp. has completed Cohort 7 in its ongoing Phase 1 trial of PAS-004 for advanced cancer patients, reporting positive safety, pharmacokinetic (PK), and pharmacodynamic (PD) data. The trial aims to evaluate the drug's effects and safety profile, contributing to the company's development pipeline in oncology. Positive trial results could significantly enhance the company's product portfolio and investor confidence.

Pasithea Therapeutics Corp. (KTTA) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. This surge in activity may reflect broader market trends or specific developments related to the company's operations or strategic initiatives. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential operational aspects.

Pasithea Therapeutics Corp. announced positive pharmacokinetic data for its PAS-004 tablet in an ongoing Phase 1/1b trial involving adult patients with Neurofibromatosis type 1 (NF1). The results indicate favorable absorption and distribution characteristics, supporting further development of PAS-004 as a potential treatment for NF1. The trial aims to evaluate the safety and efficacy of the drug, with the company expressing optimism about the implications of these findings for future clinical applications. Positive PK data from the trial could significantly enhance the company's product pipeline and investor sentiment.

Pasithea Therapeutics Corp. (KTTA) announced positive Phase 1 clinical trial results for its drug PAS-004, showing a partial response in patients with advanced cancer. The study demonstrated monotherapy clinical activity and a favorable safety profile, indicating potential for further development in cancer treatment. Positive Phase 1 data suggests significant potential for PAS-004, which could enhance the company's market position and investor sentiment.

Pasithea Therapeutics Corp. has activated a clinical trial site at the University of Alabama at Birmingham for its ongoing Phase 1/1b trial of PAS-004, targeting adult patients with Neurofibromatosis Type 1 (NF1). This trial aims to evaluate the safety and efficacy of PAS-004 in this patient population, marking a significant step in the company's research efforts. Activating a clinical trial site for a targeted treatment in a specific patient population is a significant strategic move that could enhance the company's market position and investor sentiment.

Pasithea Therapeutics Corp. has activated clinical trial sites in South Korea for its Phase 1/1b trial of PAS-004, targeting adult patients with Neurofibromatosis Type 1 (NF1). This trial aims to evaluate the safety and efficacy of PAS-004, a novel treatment option for NF1, which is a genetic disorder characterized by the growth of tumors on nerves. The activation of these sites marks a significant step in the company's clinical development strategy. Activation of clinical trial sites for a novel treatment in a specific patient population indicates a significant advancement in Pasithea's development pipeline.

Pasithea Therapeutics Corp. has announced the enrollment of Cohort 2 in its ongoing Phase 1/1b clinical trial of PAS-004 for adult patients with Neurofibromatosis type 1 (NF1), following a positive recommendation from the Safety Review Committee. This advancement indicates progress in the trial and potential for further development of PAS-004 as a treatment option for NF1 patients. The positive SRC recommendation and enrollment of a new cohort in a clinical trial could significantly influence the company's future performance and investor sentiment.

Pasithea Therapeutics Corp. (KTTA) announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, where the company will present its latest developments and strategic initiatives. This event provides a platform for KTTA to engage with investors and showcase its advancements in therapeutic solutions. Participation in a significant investment conference may enhance investor engagement and market visibility.

Pasithea Therapeutics Corp. has completed enrollment and initial dosing of the first cohort in its Phase 1/1b clinical trial of PAS-004, targeting adult patients with Neurofibromatosis Type 1 (NF1). This milestone marks a significant step in the development of PAS-004, which aims to address unmet medical needs in this patient population. The trial's progress is expected to provide valuable insights into the safety and efficacy of the treatment. Completion of enrollment and dosing in a clinical trial for a targeted treatment represents a significant advancement in the company's product pipeline and potential market positioning.

Pasithea Therapeutics Corp. has appointed an expert in ETS2-driven inflammatory diseases to its Scientific Advisory Board. This addition aims to enhance the company's research and development efforts in addressing inflammatory conditions, aligning with its strategic focus on innovative therapies. The appointment may moderately influence product innovation and research capabilities, but its overall impact on the company's trajectory is expected to be limited.

Pasithea Therapeutics Corp. announced preclinical data showing that its drug PAS-004 significantly inhibits ETS2 signaling, a key driver of inflammation in diseases like inflammatory bowel disease (IBD) and ankylosing spondylitis. Conducted at the Francis Crick Institute, the study demonstrated that PAS-004 outperformed the FDA-approved MEK inhibitor selumetinib in reducing ETS2 target genes and macrophage functions associated with chronic inflammation. The findings suggest PAS-004 could be a promising oral treatment option for inflammatory diseases, with potential to target multiple cytokines, including those not affected by current therapies. The company is optimistic about further clinical trials and the drug's market potential. The preclinical results indicate a significant advancement in treatment options for inflammatory diseases, potentially altering the company's trajectory and market position.

Pasithea Therapeutics has initiated a Phase I/Ib trial for PAS-004, a MEK inhibitor, targeting adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas. The trial will assess tolerability, safety, pharmacodynamics, and pharmacokinetics, while also determining preliminary anti-tumor activity and a recommended dose for Phase II trials. The first trial site is Royal North Shore Hospital in Sydney, with enrollment expected to start in Q2. Additional sites will open in Australia, the US, and South Korea. The trial will consist of two parts, enrolling up to 24 subjects in Part A to identify the recommended dose for Part B, which will involve continuous treatment cycles. CEO Dr. Tiago Reis Marques expressed optimism about the drug's tolerability and the financial benefits from Australia's R&D Tax Incentive. The trial's progression and potential efficacy of PAS-004 could significantly impact Pasithea's market position and investor sentiment.

Pasithea Therapeutics Corp. has announced the initiation of a Phase 1/1B clinical study for PAS-004, targeting adult patients with Neurofibromatosis Type 1 (NF1). The company has activated its first clinical trial site as part of this study, which aims to evaluate the safety and efficacy of PAS-004 in this patient population. The initiation of a clinical study for a targeted treatment in a specific patient population could significantly impact the company's future performance and investor sentiment.

Pasithea Therapeutics Corp. announced the closing of a $5 million public offering of 3,571,428 shares of common stock and accompanying warrants. The offering price was set at $1.40 per share, with Series C and D warrants also issued. Investors exercised Series D warrants for an additional $1.3 million, bringing total gross proceeds to approximately $6.3 million. The funds will be used for general corporate purposes, including ongoing research, clinical trials, and potential acquisitions. The offering was conducted under a registration statement filed with the SEC. The capital raised will support ongoing research and development efforts, which could moderately influence the company's future performance.

Pasithea Therapeutics Corp. has priced a secondary offering of 3.57 million shares at $1.40, expecting gross proceeds of approximately $5 million. The net proceeds will be used for general corporate purposes, including ongoing research, clinical trials, and potential acquisitions. H.C. Wainwright served as the sole book-running manager for the offering. The secondary offering and intended use of proceeds may moderately influence the company's financial performance and product development.

Pasithea Therapeutics Corp. announced a public offering of 3,571,428 shares of common stock and accompanying warrants at a price of $1.40 per share, aiming to raise approximately $5 million. The offering is expected to close on or about May 7, 2025, and proceeds will be used for general corporate purposes, including ongoing research and clinical trials. H.C. Wainwright & Co. is the exclusive placement agent for the offering. The securities are being offered under a registration statement filed with the SEC. The public offering may provide necessary funding for ongoing research and development, impacting financial performance and product innovation.